Allergan, Inamed Smooth Out Concerns Over Reloxin

Law360, New York (May 14, 2007, 12:00 AM EDT) -- Botox marketer Allergan Inc. and Inamed Corp. have agreed to divest the rights to rival wrinkle buster Reloxin to alleviate concerns over the potential anti-competitive effects of their billion-dollar merger.

Allergan will sell off the rights to make and distribute Reloxin to resolve U.S. Federal Trade Commission’s charges that its $3.2 billion acquisition of Inamed would break antitrust laws, the FTC said Monday.

The FTC alleged that Allergan’s takeover of Inamed, which owns the rights to Reloxin, would add a few worry lines to competition regulators...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.